Notable insider buying and selling activity across public companies.
Tracking and analysis of reported insider transactions, including executive and director buying or selling. Insider activity can offer insight into internal confidence, valuation perceptions, and potential inflection points.
3,621 total articles
Alphabet Inc. Chief Executive Pichai Sundar sold 30,521 shares of Class C Capital Stock on January 21, 2026, in a transaction totaling $10,637,367, according to a Form 4 filed with the SEC. The sale reduced his direct holdings of Class C stock to 2,211,872 shares while he continues to own 227,560 shares of Class A common stock. The filing arrives a…
Mitsui Sumitomo Insurance Co., Ltd. increased its ownership in W.R. Berkley by acquiring nearly 698,000 shares valued at $46.9 million across three transactions in January 2026. These equity purchases, conducted as part of a previously established Rule 10b5-1 trading plan, highlight sustained investment by a key shareholder amidst evolving company …
Jesse E. Gary, President and CEO of Century Aluminum, divested 150,000 shares at an average price of $48.19 per share, accumulating over $7.2 million in proceeds. This transaction occurred as the stock traded close to its 52-week high and followed a structured trading plan under Rule 10b5-1. Despite recent misses on earnings targets, Century Alumin…
Eagle Point Credit Management LLC and Eagle Point DIF GP I LLC, both significant stakeholders in ACRES Commercial Realty Corp, executed sales of the company's 7.875% Series D Preferred Stock in late January 2026, liquidating 1,892 shares for approximately $39,494. Despite these sales, ACRES demonstrates strong liquidity and solid returns with a low…
John P. Barnes, a director at M&T Bank Corp, executed the sale of nearly 18,000 shares last month, totaling approximately $3.9 million. This transaction occurred amid the bank’s robust fourth-quarter results for 2025, which included earnings surpassing analyst expectations and a steady revenue stream. Investor sentiment remains positive, reflected …
On January 21, 2026, Dakota Gold Corp.'s Chief Financial Officer, Shawn Campbell, sold 55,000 shares of the company's common stock, generating approximately $346,291 in proceeds. This transaction was conducted with share prices ranging between $6.225 and $6.44. Subsequently, Campbell's spouse retains indirect ownership of 296,736 shares while Campb…
On January 20, 2026, Bulldog Investors, LLP, alongside partners Phillip Goldstein and Andrew Dakos, acquired 678 shares of MFS High Yield Municipal Trust (NYSE: CMU) at $3.50 per share, totaling approximately $2,373. The fund, trading close to its 52-week high, offers a 5.59% dividend yield and has sustained consistent payouts for four decades. Fol…
Kushel J. Richard, Senior Managing Director at BlackRock, executed a notable stock sale of 20,000 shares valued at $22.5 million and simultaneously exercised options to acquire an additional 20,000 shares at a considerably lower price. These transactions come amid BlackRock’s recent strong financial performance and optimistic analyst revisions, fur…
Charles Peter Kirol, Peloton Interactive's Chief Operating Officer, sold 3,399 shares valued at approximately $19,895 on January 21, 2026. The sale, executed under a pre-established trading plan, coincides with an 8.37% drop in Peloton's stock price over the past week. Despite this decline, some analysts view the stock as potentially undervalued wi…
Gan Hong, Chief Science Officer at SES AI Corporation, completed the sale of 250,000 Class A Common Stock shares totaling approximately $624,705 through market transactions that took place in late January 2026. The sales coincided with the exercise of stock options for the same number of shares at a nominal price. SES AI recently reported substanti…
Kristen Robinson, director at Planet Labs PBC, executed a share sale worth nearly $1.3 million on January 21, 2026, amid soaring stock prices and a recent major government contract. Despite impressive recent returns and strategic growth initiatives, the company faces valuation scrutiny and continued unprofitability.
Gadde Vijaya, a director at Planet Labs PBC, executed the sale of 20,000 Class A Common Stock shares on January 22, 2026, totaling approximately $535,350. The sale comes as the company reached significant stock price milestones and secured a notable multi-year satellite services contract with the Swedish Armed Forces. These events have prompted upw…
Eric Siemers, Chief Medical Officer of Acumen Pharmaceuticals, carried out sales of 3,226 shares of the company’s stock in late January 2026 to satisfy tax liabilities on vested restricted stock units. These transactions occurred under a Rule 10b5-1 plan and do not indicate new insider sentiment. Concurrently, Acumen continues to advance its Alzhei…
Daniel Joseph O’Connell, CEO of Acumen Pharmaceuticals, completed the sale of over 12,000 shares to satisfy tax liabilities tied to restricted stock units, under a pre-established trading plan. The company, focused on Alzheimer’s treatments, recently reported a net loss but continues progress in its clinical trials and collaboration with JCR Pharma…
Matt Zuga, Chief Financial Officer of Acumen Pharmaceuticals, completed stock sales totaling 4,160 shares valued at approximately $7,600 in late January 2026. These transactions were made to satisfy tax withholding obligations linked to vested restricted stock units, following a Rule 10b5-1 plan. Acumen remains focused on progressing Alzheimer’s tr…
On January 22, 2026, Lindblad Sven-Olof, a director and substantial shareholder of Lindblad Expeditions Holdings, Inc., sold 62,100 shares of the company's common stock, executing the transaction near the 52-week high price. The sale was conducted under a Rule 10b5-1 trading plan, generating proceeds exceeding $1 million. Amidst revenue growth and …
Derek M Meisner, Chief Legal Officer and Corporate Secretary of Acumen Pharmaceuticals, Inc., has conducted stock sales totaling $16,720 over three days in January 2026 under a pre-planned trading arrangement. These transactions come as the company continues to focus on its Alzheimer's treatment pipeline, including progressing clinical trials and c…
Aaron Tachibana, serving as CFO and COO of Personalis, Inc., engaged in significant insider transactions involving the purchase and sale of company shares on January 22, 2026. Concurrently, Personalis moves forward with Medicare reimbursement coverage for its advanced cancer monitoring tests and contemplates a sizable stock offering as it prepares …
Shannon L. Devers, Executive Vice President and Chief Human Resources Officer at Ionis Pharmaceuticals, completed a sale of nearly $323,500 worth of stock in late January 2026. The transaction occurred near the company’s 52-week high and precedes an anticipated earnings announcement. Meanwhile, Ionis continues progressing with recent regulatory app…
Chris Wren, Vice President of Operations at Planet 13 Holdings Inc, liquidated 30,000 company shares in late January 2026, amid the company's efforts to pivot its strategy following less-than-expected third-quarter earnings. Planet 13 reported $23.3 million in revenue and a negative EPS, prompting strategic exits including the California market to …
Amprius Technologies’ Chief Technology Officer, Stefan Constantin Ionel, recently sold over half a million shares totaling around $6.83 million while simultaneously exercising stock options. This activity unfolds during a period of significant stock appreciation and notable company initiatives including a new CEO transition and expanded production …
Michael F. MacLean, CFO of Avidity Biosciences Inc, executed a sale of 4,542 shares worth roughly $329,067 on January 21, 2026, in conformity with company equity incentive policies. The stock transaction occurred near its 52-week peak at $72.74 following a significant annual stock performance gain. In parallel, Avidity unveiled a Managed Access Pro…
Steven George Hughes, Chief Medical Officer at Avidity Biosciences, sold nearly 4,900 shares worth $354,642 to satisfy tax obligations related to recently vested Restricted Stock Units. This sale precedes multiple strategic developments at Avidity, including a new FDA-backed access program for its investigational muscular dystrophy therapy and an i…
W. Michael Flanagan, Chief Scientific Officer at Avidity Biosciences, recently sold 6,534 shares valued at approximately $473,388 to fulfill tax requirements related to restricted stock units. Meanwhile, Avidity is rolling out a Managed Access Program for its drug targeting Duchenne muscular dystrophy and has agreed to be acquired by Novartis in a …
On January 21, 2026, Avidity Biosciences’ President and CEO, Sarah Boyce, executed a sale of 14,387 shares in the company valued at approximately $1.04 million. The transaction, conducted near the stock's 52-week high, was performed to fulfill tax withholding on recently vested restricted stock units, as stipulated by the company's equity incentive…
